Study: Colon X-ray seen as effective at spotting cancer

ATLANTA -- A long-awaited federal study of an X-ray alternative to the dreaded colonoscopy confirms its effectiveness at spotting most cancers, although it was far from perfect.

Medicare is already considering paying for this cheaper, less intrusive option that could persuade more people to get screened for colon cancer. And some experts believe the new method may boost the 50 percent screening rate for a cancer that is the country's second biggest killer.

"We're talking about for the first time really screening the population," said Dr. Carl Jaffe, an imaging expert at the National Cancer Institute who was not involved in the research.

In the new study, the largest of its kind, the so-called "virtual colonoscopy" identified nine out of 10 people who had cancers and large growths seen by regular colonoscopies.

But there were flaws, too. Among them: The radiologists sometimes misread the X-ray, leading them to spot polyps that weren't there. That led to unnecessary follow-up testing.

The X-ray test's real value may be in showing who really needs a regular colonoscopy -- it was better at ruling cancer out than it was at detecting it, suggests the report in today's New England Journal of Medicine.

Colorectal cancer will claim about 50,000 lives this year. The point of screening, widely recommended at age 50, is to find growths before they turn cancerous.

The gold standard is colonoscopy, in which a long, thin tube equipped with a small video camera is snaked through the large intestine to view the lining. Any growth can be removed during the procedure.

It requires general anesthesia and a missed day of work, not to mention preparation that uses pills or liquids to clean out the bowel.

The study focused on CT colonography, also known as virtual colonoscopy. It's a super X-ray of the colon that is quicker, cheaper and easier on the patient than traditional colonoscopies.

It, too, requires the bowel clean-out and has a potentially serious drawback -- radiation.

Colonoscopies cost up to $3,000. The X-ray test costs $300 to $800; most insurers don't cover it so far, but Medicare is considering it.

Insurers likely will weigh the new study heavily in their coverage decisions, said Dr. Durado Brooks, who oversees colorectal and prostate cancer programs at the American Cancer Society.

Preliminary, unpublished data from the new study already helped persuade the cancer society and others to put out guidelines in March that added virtual colonoscopy and a stool DNA test to the recommended arsenal of screenings for colon cancer, Brooks said.

In the new study, both the standard colonoscopy and the X-ray test were given to 2,531 people at 15 U.S. medical centers.

The scans showed large growths in about one in six people, although some were false alarms not confirmed by colonoscopy.

Of the patients with growths verified by colonoscopy, 90 percent were flagged through the X-ray scans.

"That's very good news," said Dr. C. Daniel Johnson, the lead author of the study. He is a researcher at the Mayo Clinic campus in Scottsdale, Ariz., with financial ties to one virtual colonoscopy company, GE Healthcare.

Back to the false alarms -- only one in four of those patients diagnosed with a growth actually had one, said Dr. Robert Fletcher, a retired Harvard Medical School professor who wrote an editorial accompanying the study. He is a paid consultant for a company that makes a DNA screening test for colon cancer.